News Release

New Patent Applications filed on Tetrodin

Date: October 25, 2000

CDNX Trading Symbol: WXI
World Wide Web: http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that the Company has registered 2 additional patent applications both in China and the U.S.A. The first relates to production of the drug substance. The Company is able to manufacture the drug substance at a higher purity grade and in greater volume at a manufacturing level then what has been done to date. The drug substance is the basic ingredient for the manufacture of the drug product (administered dose to humans). Due to the higher grade of purity, the Company was able to carry out the successful testing for the second patent application filing regarding potent analgesics .

Tetrodin has been developed by the Company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The Company has also begun tests on the usage of Tetrodin as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per:Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.